Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.59 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.58 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | RBP4 | P02753 | 3/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16689561 | 0.88 | NPSR1 (0.61) | HSD11B1TRPV1NPSR1RBP4GAA | |
| SCHEMBL16690842 | 0.83 | RBP4 (0.72) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL615807 | 0.80 | AVPR1A (0.63) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL3213011 | 0.76 | RBP4 (0.71) | HSD11B1TRPV1TRPA1RBP4GAA | |
| SCHEMBL613046 | 0.75 | RBP4 (0.51) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL615642 | 0.75 | AVPR1A (0.53) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL16689568 | 0.75 | RBP4 (0.69) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL14895207 | 0.74 | SMN1; SMN2 (0.66) | HSD11B1TRPV1TRPA1RBP4GAA | |
| SCHEMBL27716166 | 0.74 | NPSR1 (0.50) | HSD11B1TRPV1TRPA1NPSR1RBP4 | |
| SCHEMBL3095680 | 0.74 | HSD11B1 (0.76) | HSD11B1TRPV1TRPA1RBP4GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | HSD11B1 1608/4885TRPV1 2322/4885TRPA1 2275/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | HSD11B1 1608/4885TRPV1 2322/4885TRPA1 2275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.